The effect of PGI2 and PGI2 analogues with increased stability on platelet cAMP content and aggregation.
D000242:Cyclic AMP / Q000096:biosynthesis*; D003505:Cyclodextrins / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000494:pharmacology*; D006207:Half-Life; D006801:Humans; D006863:Hydrogen-Ion Concentration; D010974:Platelet Aggregation / Q000187:drug effects*; D011453:Prostaglandins / Q000494:pharmacology*; D011458:Prostaglandins E / Q000494:pharmacology; D011465:Prostaglandins, Synthetic / Q000494:pharmacology*; D013696:Temperature
D003505:Cyclodextrins; D011453:Prostaglandins; D011458:Prostaglandins E; D011465:Prostaglandins, Synthetic; D011464:Epoprostenol; D000242:Cyclic AMP